Can Dietary Supplements with Folic Acid or Vitamin B 6 Reduce Cardiovascular Risk? Design of Clinical Trials to Test the Homocysteine Hypothesis of Vascular Disease

Boushey C Beresford SAA Omenn GS Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995; 274:1049–1057.

Stampfer MJ Malinow MR Willett WC Newcomer LM Upson B Ullmann D A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992; 268:877–881.

Wald NJ Watt HC Law MR Weir DG McPartlin J Scott J. Homocysteine and ischaemic heart disease: Results of a prospective study with implications regarding prevention. Arch Int Med 1988; 158:862–867.

Evans RW Shaten BJ Hempel JD Cutler JA Kuller LH. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler Thromb Vasc Biol 1997; 17:1947–1953.

Alfthan G Pekkanen J Jauhiainen M Pitkaniemi J Karvonen M Tuomilehto J Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106:9–19.

Arnesen E Refsum H Bonaa KH Ueland PM Forde OH Nordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995; 24:704–709.

Malinow MR Ducimetiere P Luc G Evans AE Arvelier D Cambien F Plasma homocyst(e)ine levels and graded risk for myocardial infarction: Findings in two populations at contrasting risk for coronary heart disease. Atherosclerosis 1996; 126:27–34.

Graham IM Daly LE Refsum HM Robinson K Brattstrom LE Ueland PM Plasma homocysteine as a risk factor for vascular disease: The European Concerted Action Project. JAMA 1997; 277:1775–1781.

Verhoef P Kok FJ Kruyssen DA Schouten EG Witteman JC Grobbee DE Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17:989–995.

Schwartz SM Siscovick DS Malinow MR Rosendaal FR Beverly RK Hess DL Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96:412–417.

Loehrer FM Angst CP Haefeli WE Jordan PP Ritz R Fowler B. Low whole-blood S-adenosylmethionine and correlation between 5-methyltetrahydrofolate and homocysteine in coronary artery disease. Arterioscler Thromb Vasc Biol 1996; 16:727–733.

Verhoef P Stampfer MJ Buring JE Gaziano JM Allen RH Stabler SP Homocysteine metabolism and risk of myocardial infarction: Relation with vitamins B-6, B-12 and folate. Am J Epidemiol 1996; 143:845–859.

von Eckardstein A Malinow MR Upson B Heinrich J Schulte H Schonfeld R Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men. Arterioscler Thromb 1994; 14:460–464.

Genest JJ Jr McNamara JR Salem DN Wilson PW Schaefer FJ Malinow MR Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol 1990; 16:1114–1119.

Hopkins PN Wu LL Wu J Hunt SC James BC Vincent GM Higher plasma homocyst(e)ine and increased susceptibility to adverse effects of low folate in early familial coronary artery disease. Arterioscler Thromb Vasc Biol 1995; 15:1314–1320.

Panoharuniti N Lewis CA Sauberlich HE Perkins LL Go RC Alvarez JO Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr 1994; 59:940–948.

Robinson K Mayer EL Miller DP Green R van Lente F Gupta A Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995; 92:2825–2830.

Dalery K Lussier Cacan S Selhub J Davignon J Latour Y Genest J Jr. Homocysteine and coronary artery disease in French Canadian subjects: Relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am J Cardiol 1995; 75:1107–1111.

Ubbink JB Vermaak WJH Bennett PJ van Staden DA Bisbort S. The prevalance of hyperhomocysteinemia and hypercholesterolaemia in angiographically defined coronary heart disease. Klin Wochenschr 1991; 69:527–534.

Blacher J Montalescot G Ankri A Chadefaux Vekemans B Benzidia R Grosgogeat Y Hyperhomocysteinemia in coronary artery diseases. Apropos of a study on 102 patients. Arch Mal Coeur Vaiss 1996; 89:1241–1246.

Malinow MR Sexton G Auerbach M Grossman M Wilson D Upson B. Homocyst(e)inemia in daily practice. Coronary Artery Dis 1990; 1:215–220.

Lolin Yl Sanderson JE Cheng SK Chan CF Pang CP Woo KS Hyperhomocysteinaemia and premature coronary artery disease in the Chinese. Heart 1996; 76:117–122.

Israelsson B Brattstrom LE Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988; 71:227–233.

Brattstrom L Israelsson B Norrving B Bergquist D Thorne J Hultberg B Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis 1990; 81:51–60.

Coull BM Malinow MR Beamer N Sexton G Nordt F deGarmo P. Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke. Stroke 1990; 21:572–576.

Verhoef P Hennekens CH Malinow MR Kok FJ Willett WC Stampfer MJ. A prospective study of plasma homocyst(e)ine and risk of ischemic stroke. Stroke 1994; 10:1924–1930.

Indgren A Brattstrom L Norrving B Hultberg B Andersson A Johansson BB. Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 1995; 26:795–800.

Petri M Roubenoff R Dallal GE Nadeau MR Selhub J Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosis. Lancet 1996; 348:1120–1124.

Perry IJ Refsum H Morris RW Ebrahim SB Ueland PM Shaper AG. Prospective study of serum total homocysteine and risk of stroke in middle-aged British men. Lancet 1995; 346:1395–1398.

Evers S Koch HG Grotemeyer KH Lange B Deufel T Ringelstein EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol 1997; 54:1276–1282.

Molgaard J Malinow MR Lassvik C Holm AC Upson B Olsson AG. Hyperhomocyst(e)inemia: An independent risk factor for intermittent claudication. J Int Med 1992; 231:273–279.

Bergmark C Mansoor MA Swedenborg J deFaire U Svardal AM Ueland PM. Hyperhomocysteinemia in patients operated for lower extremity ischaemia below the age of 50 - effect of smoking and extent of disease. Eur J Vasc Surg 1993; 7:391–396.

Valentine RJ Kaplan HS Green R Jacobsen DW Myers SI Clagett GP. Lipoprotein(a), homocysteine and hypercoagulable states in young men with premature peripheral atherosclerosis: A prospective controlled analysis. J Vasc Surg 1996; 23:53–61.

Malinow MR Kang SS Taylor LM Coull B Inahara T Mukerjee D Prevalence of hyperhomocyst(e)inemia in patients with peripheral occlusive disease. Circulation 1989; 79:1180–1188.

Taylor LM DeFrang RD Harris EJ Porter JM. The association of elevated plasma homocysteine with progression of peripheral vascular disease. J Vasc Surg 1991; 13:129–136.

Cheng SW Ting AC Wong J. Fasting total plasma homocysteine and atherosclerotic peripheral vascular disease. Ann Vasc Surg 1997; 11:217–223.

Nygard O Nordrehaug JE Refsum H Ueland PM Farstad M Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230–236.

Stampfer MJ Malinow MR. Can homocysteine lowering reduce cardiovascualr risk? N Engl J Med 1995; 332:328–329.

Graham I Meleady R. Heart attacks and homocysteine. BMJ 1996; 313:1419–1420.

Homocysteine Lowering Trialist's Collaboration Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ 1998; 316:894–898.

Selhub J Jacques PF Wilson PW Rush D Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693–2698.

Bates CJ Mansoor MA van der Pols J Prentice A Cole TJ Finch S. Plasma total homocysteine in a representative sample of 972 British men and women aged 65 and over. Eur J Clin Nutr 1997; 51:691–697.

Daly S Mills JL Molloy A Conley M Lee YJ Kirke PN Minimum effective dose of folic acid for food fortification to prevent neural tube defects. Lancet 1997; 350:1666–1669.

Stabler SP Allen RH Savage DG Lindenbaum J. Clinical spectrum and diagnosis of cobalamin deficiency. Blood 1990; 76:871–881.

Savage DG Lindenbaum J. Folate-cobalamin interactions. In Bailey LB (editor): Folate in health and disease. New York: Marcel Dekker Inc; 1995. pp. 237–285.

Lindenbaum J Healton EB Savage DG Brust JCM Garrett TJ Podell ER Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis. N Engl J Med 1988; 318:1720–1728.

Cambell NRC. How safe are folic acid supplements? Arch Int Med 1996; 156:1638–1644.

Robinson K Arheart K Refsum H Brattstrom L Boers G Ueland P Low circulating folate and vitamin B6 concentrations: Risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 1998; 97:437–443.

Rimm EB Willett WC Hu FB Sampson L Colditz G Manson JA Folate and vitamin B-6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279:359–364.

Bostom AG Jacques PF Nadeau MR Williams RR Elliston RC Selhub J. Postmethionine load hyperhomocysteinemia in persons with normal fasting total plasma homocysteine: Initial results from the NHLBI∗ Family Heart Study. Atherosclerosis 1995; 116:147–151.

Mudd SH Skovby F Levy HL Pettigrew KD Wilcken B Pyeritz RE The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet 1985; 37:1–31.

Wilcken DE Wilcken B. The natural history of vascular disease in homocystinuria and the effects of treatment. J Inherit Metab Dis 1997; 20:295–300.

Landgren F Israelsson B Lindgren A Hultberg B Andersson A Brattstrom L. Plasma homocysteine in acute myocardial infarction: Homocysteine-lowering effect of folic acid. J Int Med 1995; 237:381–388.

den Heijer M Brouwer IA Bos GMJ Blom HJ Spaans AP Rosendaal FR Vitamin supplementation reduces blood homocysteine levels: A controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscl Thromb Vasc Biol 1998; 18:356–361.

Ubbink JB Vermaak WJH van der Merwe A Becker PJ Delport R. Potgieter HC. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994; 124:1927–1933.

Ubbink JB van der Merwe A Vermaak WJH Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Invest 1993; 71:993–998.

Naurath HJ Joosten E Riezler R Stabler SP Allen RH Lindenbaum J. Effects of vitamin B₁₂, folate, and vitamin B₆ supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 346:85–89.

Dierkes J. Vitamin requirements for the reduction of homocysteine blood levels in healthy young women. PhD thesis, University of Bonn; 1995.

Woodside JV Yarnell JWG Young IS McCrum EE Patterson CC Gey F The effects of oral vitamin supplementation on cardiovascular risk factors [abstracts]. Proc Nutr Soc 1997; 56:149 A.

Cuskelly G McNulty W McPartlin J Strain JJ Scott JM. Plasma homocysteine response to folate intervention in young women [abstracts]. Ir J Med Sci 1995; 164:3.

Saltzman E Mason JB Jacques PF Selhub J Salem D Schaefer EJ B vitamin supplementation lowers homocysteine levels in heart disease [abstracts]. Clin Res 1994; 42:172A.

Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Study (4S). Lancet 1994; 344:1383–1389.

Sacks FM Pfeffer MA Moye LA Rouleau JL Rutherford JD Cole TG The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001–1009.

Shepherd J Cobbe SM Ford I Isles CG Lorimer AR Macfarlane PW For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333:1301–1307.